Wanglong Deng

837 citations
24 papers · 622 · 1 hit paper · h-index 11

Impact in

  • Hepatology top 5%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Cancer, Hypoxia, and Metabolism
    • Cancer Genomics and Diagnostics

Papers in

Wanglong Deng

22 papers receiving 613 citations

Wanglong Deng's Hit Papers

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial 2022 · 174 citations
1740+1+2Years since publication50100150

Peers

Wanglong Deng
Comparison fields: 5 of 57
  • Hepatology 138
  • Cancer Research 82
  • Oncology 94
  • Pathology and Forensic Medicine 69
  • Genetics 31
Replace Sen Guo with:
Sen Guo China
Yixiong Liu China
Piero Gaglia Italy
Dahong Teng China
Carmela Iglesias Spain
Jinfang Zheng China
Robin Guo United States
Xiaochun Ni China
Wanglong Deng relative to Sen Guo China Sen Guo's profile →
Citations per field
00.5×2×3×4×4.5×
Sen Guo · 1×
Citations per year

Countries citing papers authored by Wanglong Deng

Since Specialization
Citations

This map shows the geographic impact of Wanglong Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanglong Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanglong Deng more than expected).

Fields of papers citing papers by Wanglong Deng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanglong Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanglong Deng. The network helps show where Wanglong Deng may publish in the future.

Co-authors

The 25 scholars most cited alongside Wanglong Deng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wanglong Deng Line = papers co-authored together Wanglong Deng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Hit paper breakdown →
2022174
2 2017104
3 202051
4 201548
5 201744
6 201737
7 201030
8 202328
9 202419
10 201712
11 202312
12 202210
13 202210
14 20249
15 20228
16 20227
17 20236
18 20254
19 20173
20 20183

About Wanglong Deng

Wanglong Deng is a scholar working on Clinical Biochemistry, Cancer Research, Genetics, Hepatology and Oncology, having authored 24 papers that have together received 622 indexed citations. Recurring topics across this work include Adrenal and Paraganglionic Tumors (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Protein Degradation and Inhibitors (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Sarcoma Diagnosis and Treatment (2 papers), Bacterial Identification and Susceptibility Testing (2 papers), Glioma Diagnosis and Treatment (2 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Hepatology (138 citations), Cancer Research (82 citations), Oncology (94 citations), Pathology and Forensic Medicine (69 citations) and Genetics (31 citations). Wanglong Deng has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Yang Liu, Chengde Wang, Jinghong Xu, Ying Yuan, Chenhan Zhong, Chenglin Liu, Dong Xu, Yanqin Huang, Lizhen Zhu and Xuefeng Fang. Their work appears in journals such as Oncotarget, Frontiers of Medicine, Infection and Drug Resistance, Nature Communications and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact